References to accompany the September 2017 issue of Kai TIaki Nursing New Zealand

1. Wise, R. & Koob, G. (2014) The development and maintenance of drug addiction. Neuropsychopharmacology. 39: 254-262
2. Koob, G. & Volkow, N. (2010). Neurocircuitry of addiction. Nature Reviews Neuropsychopharmacology. 35: 217-238.
3. Szalavitz, M. (2015). No more addictive personality. Nature. 522: S48-S49.
4. NZ Drug Foundation (ND). Drugs in New Zealand. Accessed February 2017. https://www.drugfoundation.org.nz/drug-information/drugs-in-new-zealand
5. Ministry of Health NZ. (2017). Amphetamine use 2015/2016: New Zealand Health Survey. Accessed July 2017. http://www.health.govt.nz/publication/amphetamine-use-2015-16-new-zealand-health-survey
6. McFadden Consultancy. (2016). Research Report: The New Zealand Drug Harm Index 2016 (2nd ed.). Wellington: Ministry of Health. 
7. UNODC United Nations Office on Drugs and Crime. (2016). World drug report.  Accessed July 2017. https://www.unodc.org/doc/wdr2016/WORLD_DRUG_REPORT_2016_web.pdf
8. Nutt, D. et al. (2015). The dopamine theory of addiction: 40 years of highs and lows. Nature Reviews Neuroscience. 16: 305-312. 
9. Hasin, D. et al. (2013). DSM-5 criteria for substance abuse disorders: recommendations and rationale. American Journal of Psychiatry. 170: 834-851.
10. O’Brian, C. (2011). Addiction and dependence in DSM-V. Addiction. 106(5): doi:10.1111/j.1360-0443.2010.03144.x
11. Rang, H. et al. (2016). Rang & Dale’s Pharmacology. (8^th ed.). Elsevier.
12. Everitt, B. & Heberlein, U. (2013). Addiction. Current Opinion in Neurobiology. 23: 463-466.
13. Bourzac, K. (2015). Rewiring the brain. Nature. 522: S50-S52. 
14. Nutt, D., King, L. & Phillips, L. (2010). Drug harms in the UK: a multicriteria decision analysis. The Lancet. 376: 1558-1565.
15. Darke, S., Kaye, S. & Duflou, J. (2017). Rates, characteristics and circumstances of methamphetamine-related death in Australia: a national 7-year study. Addiction. DOI:10.1111/add.13897
16. Global Drug Survey (2017). Accessed August 2017. https://www.globaldrugsurvey.com/wp-content/themes/globaldrugsurvey/results/GDS2017_key-findings-report_final.pdf
17. Degenhardt, L. et al. (2016). Estimating the number of regular and dependent methamphetamine users in Australia, 2002-2014. Medical Journal of Australia. 204(4): 153.
18. BPAC. (2014). Helping patients cope with chronic non-malignant pain: it’s not about opioids. Best Practice Journal 63. Accessed July 2017:  www.bpac.org.nz/BPJ/2014/September/chronicpain.aspx.
19. Els, C. et al. (2016). High-dose opioids for chronic non-cancer pain: an overview of Cochrane reviews. Accessedn July 2017. http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012299/full
20. HQSC: health Quality & Stafety Commission New Zealand. (2016). Atlas of healthcare variations: Opioids.  Accessed July 2017. https://www.hqsc.govt.nz/our-programmes/health-quality-evaluation/projects/atlas-of-healthcare-variation/opioids/
21. Vowles, K. et al. (2015). Rates of opioid misuse, abuse and addiction in chronic pain: a systematic review and data analysis. Pain. 156(4): 569-576.
22. Nature editorial. (2017). Battling the biology of opioid addiction. Nature Medicine. 23(7): 790.
23. Potenza, M. (2014). Non-substance addictive behaviors in the context of DSM-5. Addictive Behaviors. 39(1): 10.1016/j.addbeh.2013.09.004. http://doi.org/10.1016/j.addbeh.2013.09.004
24. NIH NIDA: National Institutes of Health (US) National Institute on Drug Abuse. (2012). Principles of drug addiction treatment: a research-based guide. (3^rd ed.). Accessed June 2017. https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition
25. Brown, T. & Alper, K. (2017). Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. The American Journal of Drug and Alcohol Abuse. doi.org/10.1080/00952990.2017.1320802
26. Noller, G., Frampton, C. & Yazar-Klosinski, B. (2017). Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. The American Journal of Drug and Alcohol Abuse. DOI: 10.1080/00952990.2017.1310218
27. Willyard, C. (2015). Quest for the quitting pill. Nature. 522: S53-S55.
28. Dunlop, K., Hanlon, C. & Downar, J. (2016). Noninvasive brain stimulation treatments for addiction and major depression. Annals of the New York Academy of Sciences. 1394: 31-54.
29. Leonard, K. (2015). Beyond the neural circuits. Nature. 522: S56.
30. Prochaska, J. & Velicer, W. (1997). The transtheoretical model of health behavior change. American Journal of Health Promotion. 12(1): 38-48.
31. Crews, F. & Boettiger, C. (2009). Impulsivity, frontal lobes and risk for addiction. Pharmacology Biochemistry and Behavior. 93(3): 237-247. 
32. Prochaska, J. Norcross, J. & Diclemente, D. (2013). Applying the stages of change. Psychotherapy in Australia. 19(2): 10-15. Accessed July 2017. http://www.psychotherapy.com.au/fileadmin/site_files/events/pdfs/APPLYING_THE_STAGES_OF_CHANGE_JOHN_NORCROSS.pdf
33. Brug, J. et al. (2005). The transtheoretical model and stages of change: a critique: Observations by five commentators on the paper by Adams, J. and White, M. (2004) Why don’t stage-based activity promotion interventions work? Health Education and Research. 20(2): 244-258.
34. Porter, J. & Jick, H. (1980). Addiction rare in patients treated with narcotics. New England Journal of Medicine. 302 (123): DOI: 10.1056/NEJM198001103020221
35. Leung, P. et al. (2017). A 1980 letter on the risk of opioid addiction. New England Journal of Medicine. 376: 2194-2195. Accessed July 2017: http://www.nejm.org/doi/full/10.1056/NEJMc1700150
36. Humphries, K. (2017). Avoiding globalisation of the prescription opioid epidemic. The Lancet. 390: 437-438.
37. Potenza, M. (2015). Behavioural addictions matter. Nature. 522: S62.
38. Miliano, C. et al., 2016. Neuropharmacology of new psychoactive substances (NPS): focus on the rewarding and reinforcing properties of cannabimimetics and amphetamine-like stimulants. Frontiers in Neuroscience. 10:153.
39. ACIC: Australian Criminal Intelligence Commission. (2017). Illicit drug data report. Accessed August 2017. https://acic.govcms.gov.au/sites/g/files/net1491/f/2017/06/illicit_drug_data_report_2015-16_full_report.pdf?v=1498019727
40. NIH NIDA: National Institutes of health National institute on drug abuse. (2017). Overdose death rates. Accessed August 2017. https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates